CoChat
Sign Up
Cited by 427

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Regulation of cargo selection in exosome biogenesis and its biomedical applications in cancer

Lee, Yu Jin, Shin, Kyeong Jin, Chae, Young Chan·2024·Experimental & Molecular Medicine
DOI 10.1038/s12276-024-01209-yPMC PMC11059157
Open this paper in CoChat — free account

Abstract

Extracellular vesicles (EVs), including exosomes, are increasingly recognized as potent mediators of intercellular communication due to their capacity to transport a diverse array of bioactive molecules. They assume vital roles in a wide range of physiological and pathological processes and hold significant promise as emerging disease biomarkers, therapeutic agents, and carriers for drug delivery. Exosomes encompass specific groups of membrane proteins, lipids, nucleic acids, cytosolic proteins, and other signaling molecules within their interior. These cargo molecules dictate targeting specificity and functional roles upon reaching recipient cells. Despite our growing understanding of the significance of exosomes in diverse biological processes, the molecular mechanisms governing the selective sorting and packaging of cargo within exosomes have not been fully elucidated. In this review, we summarize current insights into the molecular mechanisms that regulate the sorting of various molecules into exosomes, the resulting biological functions, and potential clinical applications, with a particular emphasis on their relevance in cancer and other diseases. A comprehensive understanding of the loading processes and mechanisms involved in exosome cargo sorting is essential for uncovering the physiological and pathological roles of exosomes, identifying therapeutic targets, and advancing the clinical development of exosome-based therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s12276-024-01209-y

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mechanisms of extracellular vesicle (EV) biogenesis and EV components. EV biogenesis occurs through multiple pathways, including through multivesicular bodies (MVBs) within endosomes, which leads to the secretion of exosomes, and through the plasma membrane, which results in microvesicle (MV) generation. After endocytosis, early endosomes undergo maturation in MVBs, during which they form intraluminal vesicles (ILVs) through inward membrane budding. MVBs either fuse with lysosomes for degradation or dock at the cell periphery for exosome secretion, which is facilitated by the RAB GTPases and SNARE complexes. Other types of EVs include apoptotic bodies, which are released during apoptosis via membrane budding; migrasomes, which originate from retraction fibers and contain internal vesicles; and vesicles, which are formed from amphisomes and result from the fusion of outer autophagosome membranes with late-endosomes. Exosomes carry diverse macromolecules, including signaling proteins, transcriptional regulators, various RNA species, DNA, and lipids.
Fig. 1 Mechanisms of extracellular vesicle (EV) biogenesis and EV components. EV biogenesis occurs through multiple pathways, including through multivesicular bodies (MVBs) within endosomes, which leads to the secretion of exosomes, and through the plasma membrane, which results in microvesicle (MV) generation. After endocytosis, early endosomes undergo maturation in MVBs, during which they form intraluminal vesicles (ILVs) through inward membrane budding. MVBs either fuse with lysosomes for degradation or dock at the cell periphery for exosome secretion, which is facilitated by the RAB GTPases and SNARE complexes. Other types of EVs include apoptotic bodies, which are released during apoptosis via membrane budding; migrasomes, which originate from retraction fibers and contain internal vesicles; and vesicles, which are formed from amphisomes and result from the fusion of outer autophagosome membranes with late-endosomes. Exosomes carry diverse macromolecules, including signaling proteins, transcriptional regulators, various RNA species, DNA, and lipids.CC BY · PubMed Central
Fig. 2 Exosome biogenesis mechanisms and cargo sorting pathways. Multiple molecular mechanisms of intraluminal vesicle (ILV) generation in multivesicular bodies (MVBs) have been revealed. a The classical ESCRT-dependent pathway involves the recognition of ubiquitinated proteins in the endosomal membrane by the ESCRT-0, -I, -II, and -III subcomplexes. The ATPase VPS4 cooperates in a stepwise manner to mediate ILV formation. b In the syndecan-syntenin-ALIX pathway, membrane budding and cargo clustering can occur independently of the early ESCRT machinery, with VPS4 required for the scission step. c Ceramide, which is generated from sphingomyelin by nSMase2, plays a key role in the ESCRT-independent pathway of ILV biogenesis. Ceramide can form lipid raft microdomains and trigger the conversion of ILVs into MVBs. nSMase2 is activated by FAN and can be pharmacologically inhibited by small molecules such as GW4869. The cargoes sorted through this pathway include flotillin, cholesterol, and tetraspanins, which are localized to lipid rafts.
Fig. 2 Exosome biogenesis mechanisms and cargo sorting pathways. Multiple molecular mechanisms of intraluminal vesicle (ILV) generation in multivesicular bodies (MVBs) have been revealed. a The classical ESCRT-dependent pathway involves the recognition of ubiquitinated proteins in the endosomal membrane by the ESCRT-0, -I, -II, and -III subcomplexes. The ATPase VPS4 cooperates in a stepwise manner to mediate ILV formation. b In the syndecan-syntenin-ALIX pathway, membrane budding and cargo clustering can occur independently of the early ESCRT machinery, with VPS4 required for the scission step. c Ceramide, which is generated from sphingomyelin by nSMase2, plays a key role in the ESCRT-independent pathway of ILV biogenesis. Ceramide can form lipid raft microdomains and trigger the conversion of ILVs into MVBs. nSMase2 is activated by FAN and can be pharmacologically inhibited by small molecules such as GW4869. The cargoes sorted through this pathway include flotillin, cholesterol, and tetraspanins, which are localized to lipid rafts.CC BY · PubMed Central
Fig. 3 Exosome engineering strategies for loading cancer therapeutic cargo into exosomes. Exosomes can be engineered to target internal and modified surface cargoes for cancer therapy. Cargo loading strategies are achieved by incubating therapeutic agents (e.g., pharmacological inhibitors, miRNAs, and recombinant proteins) directly with isolated exosomes (post-loading) or by exposing them to exosome-secreting donor cells, followed by the isolation of loaded exosomes (pre-loading). Post-loading methods require physical treatments to disrupt membrane integrity and allow the cargo to enter the interior of exosomes. Alternatively, exosome-producing cells with genetic expression constructs that encode therapeutic cargoes linked to an exosome sorting domain can be generated. This leads to sorting therapeutic cargo into exosomes. Modified exosomes containing tumor antigens can stimulate antigen-presenting cells and drive antitumor immune responses in the human body. Engineered exosomes can also directly release antitumor cargo to attack cancer cells.
Fig. 3 Exosome engineering strategies for loading cancer therapeutic cargo into exosomes. Exosomes can be engineered to target internal and modified surface cargoes for cancer therapy. Cargo loading strategies are achieved by incubating therapeutic agents (e.g., pharmacological inhibitors, miRNAs, and recombinant proteins) directly with isolated exosomes (post-loading) or by exposing them to exosome-secreting donor cells, followed by the isolation of loaded exosomes (pre-loading). Post-loading methods require physical treatments to disrupt membrane integrity and allow the cargo to enter the interior of exosomes. Alternatively, exosome-producing cells with genetic expression constructs that encode therapeutic cargoes linked to an exosome sorting domain can be generated. This leads to sorting therapeutic cargo into exosomes. Modified exosomes containing tumor antigens can stimulate antigen-presenting cells and drive antitumor immune responses in the human body. Engineered exosomes can also directly release antitumor cargo to attack cancer cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 113

  1. Harding, C., Heuser, J. & Stahl, P. Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding. Eur. J. Cell Biol. 35, 256–263 (1984).
  2. Shurtleff, M. J., Temoche-Diaz, M. M. & Schekman, R. Extracellular vesicles and cancer: caveat lector. Annu. Rev. Cancer Biol. 2, 395–411 (2018). · DOI
  3. Jeppesen, D. K. et al. Reassessment of exosome composition. Cell 177, 428–445 e418 (2019). · DOI · Paper page
  4. Mendt, M. et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3, e99263 (2018). · DOI
  5. Dixson, A. C., Dawson, T. R., Di Vizio, D. & Weaver, A. M. Context-specific regulation of extracellular vesicle biogenesis and cargo selection. Nat. Rev. Mol. Cell Biol. 24, 454–476 (2023). · DOI
  6. Li, S. P., Lin, Z. X., Jiang, X. Y. & Yu, X. Y. Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools. Acta Pharmacol. Sin. 39, 542–551 (2018). · DOI
  7. Gurung, S., Perocheau, D., Touramanidou, L. & Baruteau, J. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun. Signal. 19, 47 (2021). · DOI
  8. Maas, S. L. N., Breakefield, X. O. & Weaver, A. M. Extracellular vesicles: unique intercellular delivery vehicles. Trends Cell Biol. 27, 172–188 (2017). · DOI
  9. van Niel, G., D’Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228 (2018). · DOI · Paper page
  10. Buzas, E. I. The roles of extracellular vesicles in the immune system. Nat. Rev. Immunol. 23, 236–250 (2023). · DOI
  11. Ma, L. et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 25, 24–38 (2015). · DOI
  12. Sansone, P. et al. Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proc. Natl Acad. Sci. 114, E9066–E9075 (2017). · DOI
  13. Yokoi, A. et al. Mechanisms of nuclear content loading to exosomes. Sci. Adv. 5, eaax8849 (2019). · DOI
  14. Henne, W. M., Buchkovich, N. J. & Emr, S. D. The ESCRT pathway. Dev. Cell 21, 77–91 (2011). · DOI
  15. Gruenberg, J. Life in the lumen: the multivesicular endosome. Traffic 21, 76–93 (2020). · DOI
  16. Sedgwick, A. E. & D’Souza-Schorey, C. The biology of extracellular microvesicles. Traffic 19, 319–327 (2018). · DOI
  17. Juan, T. & Furthauer, M. Biogenesis and function of ESCRT-dependent extracellular vesicles. Semin. Cell Dev. Biol. 74, 66–77 (2018). · DOI
  18. Raiborg, C. & Stenmark, H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458, 445–452 (2009). · DOI · Paper page
  19. Colombo, M. et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J. Cell Sci. 126, 5553–5565 (2013).
  20. Coonrod, E. M. & Stevens, T. H. The yeast vps class E mutants: the beginning of the molecular genetic analysis of multivesicular body biogenesis. Mol. Biol. Cell 21, 4057–4060 (2010). · DOI
  21. Imjeti, N. S. et al. Syntenin mediates SRC function in exosomal cell-to-cell communication. Proc. Natl Acad. Sci. USA 114, 12495–12500 (2017). · DOI
  22. Ghossoub, R. et al. Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2. Nat. Commun. 5, 3477 (2014). · DOI
  23. Ghoroghi, S. et al. Ral GTPases promote breast cancer metastasis by controlling biogenesis and organ targeting of exosomes. Elife 10, e61539 (2021). · DOI
  24. Nkosi, D. et al. Epstein-Barr virus LMP1 promotes syntenin-1- and Hrs-induced extracellular vesicle formation for its own secretion to increase cell proliferation and migration. mBio 11, e00589-20 (2020). · DOI
  25. Fan, S. J. et al. Glutamine deprivation alters the origin and function of cancer cell exosomes. EMBO J. 39, e103009 (2020). · DOI · Paper page
  26. Lee, Y. J. et al. GPR143 controls ESCRT-dependent exosome biogenesis and promotes cancer metastasis. Dev. Cell 58, 320–334 e328 (2023). · DOI
  27. Donoso-Quezada, J., Ayala-Mar, S. & Gonzalez-Valdez, J. The role of lipids in exosome biology and intercellular communication: function, analytics and applications. Traffic 22, 204–220 (2021). · DOI
  28. Trajkovic, K. et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244–1247 (2008). · DOI
  29. Knapp, P. E. Proteolipid protein: is it more than just a structural component of myelin? Dev. Neurosci. 18, 297–308 (1996). · DOI
  30. Leidal, A. M. et al. The LC3-conjugation machinery specifies the loading of RNA-binding proteins into extracellular vesicles. Nat. Cell Biol. 22, 187–199 (2020). · DOI
  31. Wei, D. et al. RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res. 31, 157–177 (2021). · DOI
  32. Yanez-Mo, M., Barreiro, O., Gordon-Alonso, M., Sala-Valdes, M. & Sanchez-Madrid, F. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol. 19, 434–446 (2009). · DOI
  33. van Niel, G. et al. The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis. Dev. Cell 21, 708–721 (2011). · DOI · Paper page
  34. Andreu, Z. & Yanez-Mo, M. Tetraspanins in extracellular vesicle formation and function. Front. Immunol. 5, 442 (2014). · DOI
  35. Fordjour, F. K., Guo, C., Ai, Y., Daaboul, G. G. & Gould, S. J. A shared, stochastic pathway mediates exosome protein budding along plasma and endosome membranes. J. Biol. Chem. 298, 102394 (2022). · DOI
  36. Hurwitz, S. N. et al. Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers. Oncotarget 7, 86999–87015 (2016). · DOI
  37. Kugeratski, F. G. et al. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. Nat. Cell Biol. 23, 631–641 (2021). · DOI
  38. Hoshino, A. et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell 182, 1044–1061.e1018 (2020). · DOI
  39. Rieu, S., Geminard, C., Rabesandratana, H., Sainte-Marie, J. & Vidal, M. Exosomes released during reticulocyte maturation bind to fibronectin via integrin alpha4beta1. Eur. J. Biochem. 267, 583–590 (2000). · DOI
  40. Segura, E. et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 106, 216–223 (2005). · DOI
  41. Liang, Y. et al. Complex N-linked glycans serve as a determinant for exosome/microvesicle cargo recruitment. J. Biol. Chem. 289, 32526–32537 (2014). · DOI
  42. Escola, J. M. et al. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J. Biol. Chem. 273, 20121–20127 (1998). · DOI · Paper page
  43. Phuyal, S., Hessvik, N. P., Skotland, T., Sandvig, K. & Llorente, A. Regulation of exosome release by glycosphingolipids and flotillins. FEBS J. 281, 2214–2227 (2014). · DOI
  44. Arnold, P. et al. Joint reconstituted signaling of the IL-6 receptor via extracellular vesicles. Cells 9, 1307 (2020). · DOI
  45. Blanchard, N. et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J. Immunol. 168, 3235–3241 (2002). · DOI · Paper page
  46. Fu, W. et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat. Commun. 10, 4355 (2019). · DOI
  47. Nager, A. R. et al. An actin network dispatches ciliary GPCRs into extracellular vesicles to modulate signaling. Cell 168, 252–263.e214 (2017). · DOI · Paper page
  48. Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382–386 (2018). · DOI · Paper page
  49. Shelke, G. V. et al. Endosomal signalling via exosome surface TGFbeta-1. J. Extracell. Vesicles 8, 1650458 (2019). · DOI
  50. Keller, M. D. et al. Decoy exosomes provide protection against bacterial toxins. Nature 579, 260–264 (2020). · DOI
  51. Diamandis, E. P. & Plebani, M. Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker. Clin. Chem. Lab. Med. 54, e1–e2 (2016). · DOI
  52. Carnino, J. M., Ni, K. & Jin, Y. Post-translational modification regulates formation and cargo-loading of extracellular vesicles. Front Immunol. 11, 948 (2020). · DOI
  53. Sork, H. et al. Heterogeneity and interplay of the extracellular vesicle small RNA transcriptome and proteome. Sci. Rep. 8, 10813 (2018). · DOI · Paper page
  54. Kim, K. M., Abdelmohsen, K., Mustapic, M., Kapogiannis, D. & Gorospe, M. RNA in extracellular vesicles. Wiley Interdiscip. Rev. RNA 8 https://doi.org/10.1002/wrna.1413 (2017). · DOI
  55. Das, S. et al. The extracellular RNA communication consortium: establishing foundational knowledge and technologies for extracellular RNA research. Cell 177, 231–242 (2019). · DOI
  56. Fabbiano, F. et al. RNA packaging into extracellular vesicles: an orchestra of RNA-binding proteins? J. Extracell. Vesicles 10, e12043 (2020). · DOI
  57. Brinkman, K. et al. Extracellular vesicles from plasma have higher tumour RNA fraction than platelets. J. Extracell. Vesicles 9, 1741176 (2020). · DOI
  58. Batagov, A. O. & Kurochkin, I. V. Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3’-untranslated regions. Biol. Direct 8, 12 (2013). · DOI
  59. Garcia-Martin, R. et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. Nature 601, 446–451 (2022). · DOI
  60. Mittelbrunn, M. et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun. 2, 282 (2011). · DOI
  61. Stoorvogel, W. Functional transfer of microRNA by exosomes. Blood 119, 646–648 (2012). · DOI
  62. Gebauer, F., Schwarzl, T., Valcarcel, J. & Hentze, M. W. RNA-binding proteins in human genetic disease. Nat. Rev. Genet. 22, 185–198 (2021). · DOI
  63. Zhang, H. et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol. Cancer 19, 43 (2020). · DOI
  64. Li, Y. et al. Heterogeneous nuclear ribonucleoprotein A1 loads batched tumor-promoting MicroRNAs into small extracellular vesicles with the assist of caveolin-1 in A549 cells. Front Cell Dev. Biol. 9, 687912 (2021). · DOI
  65. Villarroya-Beltri, C. et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat. Commun. 4, 2980 (2013). · DOI · Paper page
  66. Chen, C. et al. Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J. Clin. Invest. 130, 404–421 (2020). · DOI
  67. Shurtleff, M. J. et al. Broad role for YBX1 in defining the small noncoding RNA composition of exosomes. Proc. Natl Acad. Sci. USA 114, E8987–E8995 (2017). · DOI
  68. Baglio, S. R. et al. Sensing of latent EBV infection through exosomal transfer of 5’pppRNA. Proc. Natl. Acad. Sci. USA 113, E587–E596 (2016). · DOI
  69. Wozniak, A. L. et al. The RNA binding protein FMR1 controls selective exosomal miRNA cargo loading during inflammation. J. Cell. Biol. 219, e201912074 (2020). · DOI
  70. Barman, B., Dawson, T. R. & Weaver, A. M. ER membrane contact sites: key platforms for biogenesis of RNA-containing extracellular vesicles. Contact 5, 25152564221121444 (2022). · DOI
  71. Thakur, B. K. et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766–769 (2014). · DOI
  72. Cai, J., Wu, G., Jose, P. A. & Zeng, C. Functional transferred DNA within extracellular vesicles. Exp. Cell Res. 349, 179–183 (2016). · DOI
  73. Hagey, D. W. et al. Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. J. Extracell. Vesicles 10, e12142 (2021). · DOI
  74. Vagner, T. et al. Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J. Extracell. Vesicles 7, 1505403 (2018). · DOI
  75. Llorente, A. et al. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim. Biophys. Acta 1831, 1302–1309 (2013). · DOI
  76. Skotland, T. et al. Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers. Eur. J. Cancer 70, 122–132 (2017). · DOI
  77. Lydic, T. A. et al. Rapid and comprehensive ‘shotgun’ lipidome profiling of colorectal cancer cell derived exosomes. Methods 87, 83–95 (2015). · DOI
  78. Haraszti, R. A. et al. High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J. Extracell. Vesicles 5, 32570 (2016). · DOI · Paper page
  79. Milane, L., Singh, A., Mattheolabakis, G., Suresh, M. & Amiji, M. M. Exosome mediated communication within the tumor microenvironment. J. Control. Release 219, 278–294 (2015). · DOI
  80. Teng, F. & Fussenegger, M. Shedding light on extracellular vesicle biogenesis and bioengineering. Adv. Sci. 8, 2003505 (2020). · DOI
  81. Shimada, Y. et al. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. Sci. Rep. 11, 7830 (2021). · DOI
  82. Matsumoto, A. et al. Accelerated growth of B16BL6 tumor in mice through efficient uptake of their own exosomes by B16BL6 cells. Cancer Sci. 108, 1803–1810 (2017). · DOI
  83. Lobb, R. J., Lima, L. G. & Moller, A. Exosomes: key mediators of metastasis and pre-metastatic niche formation. Semin. Cell Dev. Biol. 67, 3–10 (2017). · DOI
  84. Choi, D. et al. The impact of oncogenic EGFRvIII on the proteome of extracellular vesicles released from glioblastoma cells. Mol. Cell. Proteomics 17, 1948–1964 (2018). · DOI
  85. Jafari, R., Rahbarghazi, R., Ahmadi, M., Hassanpour, M. & Rezaie, J. Hypoxic exosomes orchestrate tumorigenesis: molecular mechanisms and therapeutic implications. J. Transl. Med. 18, 474 (2020). · DOI
  86. Jo, H., Shim, K. & Jeoung, D. Exosomes: diagnostic and therapeutic implications in cancer. Pharmaceutics 15, 1465 (2023). · DOI
  87. Kosgodage, U. S., Trindade, R. P., Thompson, P. R., Inal, J. M. & Lange, S. Chloramidine/bisindolylmaleimide-I-mediated inhibition of exosome and microvesicle release and enhanced efficacy of cancer chemotherapy. Int. J. Mol. Sci. 18, 1007 (2017). · DOI
  88. Kulshreshtha, A. et al. Simvastatin mediates inhibition of exosome synthesis, localization and secretion via multicomponent interventions. Sci. Rep. 9, 16373 (2019). · DOI
  89. Catalano, M. & O’Driscoll, L. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J. Extracell. Vesicles 9, 1703244 (2020). · DOI
  90. Hanson, P. I. & Cashikar, A. Multivesicular body morphogenesis. Annu. Rev. Cell Dev. Biol. 28, 337–362 (2012). · DOI
  91. Datta, A. et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: a drug repurposing strategy for advanced cancer. Sci. Rep. 8, 8161 (2018). · DOI
  92. Henkels, K. M., Muppani, N. R. & Gomez-Cambronero, J. PLD-specific small-molecule inhibitors decrease tumor-associated macrophages and neutrophils infiltration in breast tumors and lung and liver metastases. PLoS One 11, e0166553 (2016). · DOI
  93. Wang, F. et al. System Xc(-) inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance. Cancer Lett. 535, 215649 (2022). · DOI
  94. Im, E. J. et al. Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat. Commun. 10, 1387 (2019). · DOI
  95. Lee, C. H. et al. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1. Theranostics 12, 1971–1987 (2022). · DOI
  96. Rabas, N. et al. PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness. J. Cell. Biol. 220, e202006049 (2021). · DOI
  97. Cully, M. Exosome-based candidates move into the clinic. Nat. Rev. Drug Discov. 20, 6–7 (2021). · DOI
  98. Silva, A. M. et al. Quantification of protein cargo loading into engineered extracellular vesicles at single-vesicle and single-molecule resolution. J. Extracell. Vesicles 10, e12130 (2021). · DOI
  99. Corso, G. et al. Systematic characterization of extracellular vesicle sorting domains and quantification at the single molecule—single vesicle level by fluorescence correlation spectroscopy and single particle imaging. J. Extracell. Vesicles 8, 1663043 (2019). · DOI
  100. Gee, P. et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat. Commun. 11, 1334 (2020). · DOI
  101. Ye, Y. et al. An engineered exosome for delivering sgRNA:Cas9 ribonucleoprotein complex and genome editing in recipient cells. Biomater. Sci. 8, 2966–2976 (2020). · DOI
  102. Choi, H. et al. Exosome-based delivery of super-repressor IkappaBalpha relieves sepsis-associated organ damage and mortality. Sci. Adv. 6, eaaz6980 (2020). · DOI
  103. Sterzenbach, U. et al. Engineered exosomes as vehicles for biologically active proteins. Mol. Ther. 25, 1269–1278 (2017). · DOI
  104. Reshke, R. et al. Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone. Nat. Biomed. Eng. 4, 52–68 (2020). · DOI
  105. Kojima, R. et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment. Nat. Commun. 9, 1305 (2018). · DOI · Paper page
  106. Pan, Y. et al. A simple and sensitive method for exosome detection based on steric hindrance-controlled signal amplification. Chem. Commun. (Camb.) 56, 13768–13771 (2020). · DOI
  107. Yang, J. et al. Plasma-derived exosomal ALIX as a novel biomarker for diagnosis and classification of pancreatic cancer. Front Oncol. 11, 628346 (2021). · DOI
  108. Chanteloup, G. et al. Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study. J. Extracell. Vesicles 9, 1766192 (2020). · DOI
  109. McKiernan, J. et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2, 882–889 (2016). · DOI
  110. Bao, Q. et al. Extracellular vesicle RNA sequencing reveals dramatic transcriptomic alterations between metastatic and primary osteosarcoma in a liquid biopsy approach. Ann. Surg. Oncol. 25, 2642–2651 (2018). · DOI
  111. Buscail, E. et al. Liquid biopsy approach for pancreatic ductal adenocarcinoma. Cancers (Basel) 11, https://doi.org/10.3390/cancers11060852 (2019). · DOI
  112. Tang, W., Huang, C., Tang, C., Xu, J. & Wang, H. Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis. Onco Targets Ther. 9, 455–460, (2016). · DOI
  113. Chen, K. et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC). Clin. Cancer Res. 25, 7058–7067 (2019). · DOI

Cited by

Sorted by citations

Metadata

Authors
Lee, Y. J., Shin, K. J., & Chae, Y. C.
Venue
Experimental & Molecular Medicine
Publisher
Springer Science and Business Media LLC
Published
2024-04-05
Volume
56
Issue
4
Pages
877-889
ISSN
2092-6413
DOI
10.1038/s12276-024-01209-y
PMC
PMC11059157
Cited by
427
References
12
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review